Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus

Objective: Addition of vildagliptin to ongoing insulin therapy may help in terms of overall glycemic control as well as reduction in dose of insulin and weight. This study sought to evaluate the effect of vildagliptin and fixed dose combination (FDC) of vildagliptin and metformin in patients in ongoing insulin therapy for Type 2 diabetes mellitus. Materials and Methods: This was an open label, prospective, non-randomised, multicentric observational study. In this study 400 patients with T2DM on insulin were enrolled and allocated with the treatment of vildagliptin 50 mg in monotherapy and FDC of vildagliptin 50 mg and metformin strengths as 500/ 850 / 1000 mg. Baseline investigations included fasting blood glucose (FBG) and post prandial plasma glucose (PPPG) Estimation and glycosylated haemoglobin (HbA1c). Results: The combined analysis was carried out on 300 completed patients in this study, who were treated with vildagliptin or FDC of vildagliptin and metformin. The difference in mean value of insulin dose (MID) showed a highly significant decrease (P <0.0001) from baseline to end of the treatment i.e. from 36.26 ± 18.21 to 26.87 ± 16.49 IU. A highly significant decrease (P <0.0001) in FBG from 194.94 ± 56.19 to 124.93 ± 30.11 mg/dl was observed. Similarly PPPG showed a highly significant (P <0.0001) decrease from baseline to end of the treatment i.e. from 287.60 mg/dl to 172.05 mg/dl and there was highly significant (P <0.0001) decrease in HbA1c i.e. from 9.01% to 7.65% respectively. At the same time, highly significant decrease (P <0.0001) in mean weight also observed from baseline to end of the treatment i.e. from 71.23 ± 11.06 kg to 70.06 ± 10.62 Kg. Conclusion: Addition of vildagliptin and FDC of vildagliptin and metformin is an effective strategy in glycemic control, reduction in dose of insulin and weight of patients suffering with T2DM.

• Publication year

  2012

• Venue

  Indian journal of endocrinology and metabolism

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/2230-8210.94258PMID 22701828PMCID 3354946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus

  2013cited by this paper
• Department of Health and Ageing Therapeutic Goods Administration

  2013cited by this paper
• Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’

  2012cited by this paper
• Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.

  2011cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.

  2011cited by this paper
• Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

  2011cited by this paper
• Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

  2010cited by this paper
• Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use

  2008cited by this paper
• Vildagliptin: a new oral treatment for type 2 diabetes mellitus

  2008cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Reducing insulin resistance with metformin: the evidence today.

  2003cited by this paper
• Inpatient management of diabetes mellitus.

  2002cited by this paper
• Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

  2002cited by this paper
• Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.

  2001cited by this paper

• Pharmacokinetic and Bioequivalence Evaluation of Two Sitagliptin Tablets With Different Salts in Healthy Subjects

  2025cites this paper
• Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management

  2021cites this paper
• Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: the OMEGA study.

  2020cites this paper
• Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review

  2017cites this paper
• Analyzing the Factors Contributing to Withdrawal from Insulin Therapy Following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin

  2015cites this paper
• Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study

  2015cites this paper
• Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus

  2013cites this paper
• Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?

  2013cites this paper
• Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin

  2013cites this paper